Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous fecal microbiota transplantation
- Development stage
- Phase 1
- Lead developer
- MaaT Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal, Colonoscopy, Nasogastric Tube, Nasoduodenal Tube, Gastroscopy
01
Overview
Autologous fecal microbiota transplantation (aFMT) is a microbiome-based therapeutic approach that involves the collection, preservation, and subsequent reintroduction of a patient's own fecal microbiota into their gastrointestinal tract. This procedure is typically performed to restore microbial diversity and richness following medical perturbations that cause severe dysbiosis, such as intensive chemotherapy, broad-spectrum antibiotic treatment, or surgical interventions like ileostomy reversal. By replenishing the host's unique baseline commensal bacteria, aFMT aims to correct intestinal inflammation, suppress the dominance of pathobionts and multidrug-resistant organisms (MDROs), and improve metabolic or functional outcomes. Unlike allogenic FMT, which utilizes donor material, aFMT eliminates the risk of donor-acquired infections and ensures host-specific microbiome compatibility. It is currently being investigated for a wide range of indications, including acute myeloid leukemia (AML), ulcerative colitis, weight loss maintenance, and graft-versus-host disease (GVHD) prophylaxis.
- Other names
- autologous fecal microbiota therapyaFMTautologous fecal microbiota transferautologous fecal matter transplantfecal auto-transplantationautocoprobiotic
Beyond the preview
Go deeper on autologous fecal microbiota transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous fecal microbiota transplantation.